Alterity Therapeutics
ATHE
10 hedge funds and large institutions have $257K invested in Alterity Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
13% less capital invested
Capital invested by funds: $295K → $257K (-$38K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$23.3K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$2.44K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$242 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.29K |
ATHE Hedge Fund Activity: Q4 2019 in Review
10 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q4 2019, worth a combined $257K — down 13% from $295K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ATHE positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $23.3K. The largest seller was UBS Group, cutting an estimated $2.29K.
- 10 institutional investors held Alterity Therapeutics (ATHE) as of Q4 2019, up from 9 in Q3 2019.
- Funds reported $257K of Alterity Therapeutics stock for Q4 2019, down 13% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q4 2019 and 0 closed out, a net change of +2 holders.
- The largest Alterity Therapeutics buyer in Q4 2019 was Morgan Stanley, an estimated $23.3K added.
- The largest Alterity Therapeutics seller in Q4 2019 was UBS Group, an estimated $2.29K sold.
Based on aggregated 13F filings for Q4 2019.